Why do some breast cancer patients face a much higher risk of distant metastasis, while others with seemingly similar disease experience far better outcomes?
A new study published in Computational Biomedicine suggests that the answer may lie not in the expression of a single gene, but in the interaction between two genes.
Researchers have identified a previously underappreciated relationship between SUCLA2 and USP10 that strongly correlates with distant metastasis-free survival (DMFS) in breast cancer patients. More importantly, the study shows that this prognostic relationship changes dramatically depending on whether patients receive treatment, highlighting the importance of considering molecular interactions when predicting clinical outcomes.
Breast cancer remains one of the leading causes of cancer-related death worldwide. Although advances in surgery, chemotherapy, radiotherapy, endocrine therapy, and targeted therapies have significantly improved survival, distant metastasis continues to be the primary cause of mortality. Reliable biomarkers capable of identifying patients at high metastatic risk are therefore essential for guiding personalized treatment strategies.
Previous studies have suggested that SUCLA2, a mitochondrial metabolic enzyme, and USP10, a deubiquitinating enzyme involved in multiple cancer-related pathways, may individually influence tumor progression. However, whether their combined activity affects patient prognosis has remained unknown.
To address this question, the researchers analyzed gene expression and clinical data from four independent breast cancer cohorts comprising patients with available distant metastasis-free survival information. Rather than evaluating each gene separately, patients were stratified according to the combined expression patterns of SUCLA2 and USP10.
The analysis revealed a striking finding.
Patients exhibiting low SUCLA2 expression together with high USP10 expression experienced significantly poorer distant metastasis-free survival if they did not receive treatment. However, among patients who underwent treatment, this elevated metastatic risk was no longer observed. In contrast, neither SUCLA2 nor USP10 alone consistently predicted patient outcomes across the four independent cohorts.
These findings suggest that the interaction between the two genes carries clinically meaningful prognostic information that cannot be captured by either biomarker individually.
"Our results indicate that molecular interactions may provide more informative biomarkers than single-gene measurements," the researchers noted. "Considering gene interactions could improve risk stratification and support more personalized treatment decisions."
The study also raises the possibility that the SUCLA2–USP10 interaction may represent a previously unrecognized therapeutic vulnerability. If validated in future biological and clinical studies, targeting this pathway could contribute to strategies aimed at reducing metastatic progression.
Although additional experimental research will be required to uncover the underlying molecular mechanisms, the work provides important clinical evidence supporting interaction-based biomarker discovery. The authors believe this systems-level perspective may help advance precision oncology by identifying patient subgroups that respond differently to treatment despite sharing similar clinical characteristics.
As precision medicine increasingly shifts from individual genes to complex molecular networks, studies such as this demonstrate how integrating multiple biomarkers may lead to more accurate prognosis and more individualized cancer care.
